These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23144192)

  • 1. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
    Zandberg DP; Huang TY; Ke X; Baer MR; Gore SD; Smith SW; Davidoff AJ
    Haematologica; 2013 Apr; 98(4):584-90. PubMed ID: 23144192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
    Courville EL; Wu Y; Kourda J; Roth CG; Brockmann J; Muzikansky A; Fathi AT; de Leval L; Orazi A; Hasserjian RP
    Mod Pathol; 2013 Jun; 26(6):751-61. PubMed ID: 23307061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
    Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
    Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
    Nazha A; Rybicki L; Abounader D; Bolwell B; Dean R; Gerds AT; Jagadeesh D; Hamilton BK; Hill BT; Kalaycio M; Liu H; Pohlman B; Sobecks R; Sekeres MA; Majhail NS
    Bone Marrow Transplant; 2016 Dec; 51(12):1642-1643. PubMed ID: 27721371
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
    Jabbour E; Ghanem H; Huang X; Ravandi F; Garcia-Manero G; O'Brien S; Faderl S; Pierce S; Choi S; Verstovsek S; Brandt M; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):93-7. PubMed ID: 24447728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
    Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
    Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
    Bell JA; Galaznik A; Huelin R; Stokes M; Guo Y; Fram RJ; Faller DV
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e157-e166. PubMed ID: 29475821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myelodysplastic/myeloproliferative disorders: the interface.
    Bennett JM
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1095-100, v. PubMed ID: 14560776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.
    Schmid C; de Wreede LC; van Biezen A; Finke J; Ehninger G; Ganser A; Volin L; Niederwieser D; Beelen D; Alessandrino P; Kanz L; Schleuning M; Passweg J; Veelken H; Maertens J; Cornelissen JJ; Blaise D; Gramatzki M; Milpied N; Yakoub-Agha I; Mufti G; Rovira M; Arnold R; de Witte T; Robin M; Kröger N
    Haematologica; 2018 Feb; 103(2):237-245. PubMed ID: 29101205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 16. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Sanz C; Nomdedeu M; Belkaid M; Martinez I; Nomdedeu B; Pereira A
    Transfusion; 2013 Apr; 53(4):710-5. PubMed ID: 22845746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
    Quintás-Cardama A; Daver N; Kim H; Dinardo C; Jabbour E; Kadia T; Borthakur G; Pierce S; Shan J; Cardenas-Turanzas M; Cortes J; Ravandi F; Wierda W; Estrov Z; Faderl S; Wei Y; Kantarjian H; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):401-10. PubMed ID: 24875590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
    Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
    Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
    Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.